#USA #New York #Class Action #securities litigation #Replimune Group

Rise and Fall of Replimune Group's Stock

The ongoing legal situation surrounding Replimune Group, Inc. (NASDAQ: REPL) is drawing attention as shareholders who purchased securities between October 20, 2025, and April 10, 2026, may be eligible for recouping losses due to a substantial drop in stock price.

Between late 2025 and early 2026, Replimune's stock reached a peak of $10.73 per share. However, by mid-April 2026, the price had dramatically collapsed to $1.70, a staggering decline of about 84% or $9.03 per share. This massive fluctuation was triggered by the company's notifications regarding its RP1 biologics license application, which ultimately led shareholders to feel misled about the approval status of their investment.

Chronological Breakdown of Events

The timeline of events leading to this stock decline indicates how perceptions about regulatory approvals shifted, raising concerns about transparency:

• - October 20, 2025: Replimune proclaimed the FDA's acceptance of its biologics license resubmission, suggesting a green light for future approvals, thus influencing market expectations positively.
• - November 6, 2025: The company reported quarterly results affirming possible approval based on trial data, even amidst significant losses for the quarter totalling $83.1 million.
• - December 8, 2025: Shares soared to the Class Period peak of $10.73.
• - February 3, 2026: Management continued to present optimistic scenarios regarding commercial readiness, although the company suffered a $70.9 million net loss.
• - April 10, 2026: Disaster struck when the FDA issued a complete response letter rejecting the application, citing unresolved concerns about study design and inadequate data from early trials. Consequently, shares plummeted drastically by 19% before a trading halt.
• - April 13, 2026: Further communication from the FDA clarified their preference for a randomized controlled trial, resulting in an additional stock decline of 64% to $1.70.

Implications for Shareholders

The lawsuit filed by Levi & Korsinsky, LLP highlights these events as critical indicators that the company may have withheld information pertinent to investors' understanding of their stock's risk. If you're among shareholders impacted by this drastic fall from grace, you may be entitled to seek compensation. Investors are encouraged to gather brokerage records to validate their purchase history and confirm their eligibility for participation in this class action.

The filing raises questions about whether the company provided an accurate portrayal of the regulatory hurdles surrounding the approval process as the projected action dates approached. According to Joseph E. Levi, Esq., timely disclosures are vital for a functional market, and the recent fluctuations pose serious questions regarding the transparency of Replimune’s announcements.

Actions for Affected Investors

Investors worried about their losses could potentially recover funds if they purchased shares during the relevant time frame. Those who sold shares at a loss may still be eligible to join the claim, emphasizing the necessity to approach the legal representatives as soon as possible. Contact details for attorneys handling the case have been provided for those needing more information or guidance.

Conclusion

This situation serves as a reminder of the volatile nature of securities and the importance of corporate transparency. Shareholders are advised to remain vigilant about the implications of such drastic changes within their investments and seek legal advice if they believe they have been wronged. With deadlines for filing claims, now is the time for investors to take action. If you're uncertain of your standing, reach out to attorneys who specialize in securities litigation for clarity on your next steps.